HepaRegeniX appoints Dr. Andreas Busch as Senior Advisor
Dr. Busch will help the Company to further advance the development of MKK4 inhibition, a first-in-class treatment paradigm for liver resection and transplant.
HepaRegeniX reports positive topline results of its Phase 1 Clinical Trial of HRX-0215, a First-In-Class MKK4 inhibitor
HRX-0215 proved to be safe and well tolerated in healthy volunteers.
HepaRegeniX appoints Elias Papatheodorou as new Chairman of the Board of Directors
He follows Dr. Graham Dixon who served as Chairman on the Board of HeparegeniX since 2017.
HepaRegeniX to present key results on MKK4 inhibitors and their therapeutic efficacy at upcoming scientific conferences
New data supporting therapeutic potential of MKK4 inhibition in advanced liver diseases.
HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute
HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination therapy.
HepaRegeniX initiates first-in-man Phase 1 trial for its lead MKK4 inhibitor HRX‑0215
HRX-0215 is the first compound from the company´s small molecule-based drug discovery platform ready for clinical testing.
HepaRegeniX achieves further milestone related to proof of safety and efficacy for MKK4 inhibition in an advanced chronic liver disease model
New preclinical data indicate beneficial therapeutic effects in non-alcoholic steatohepatitis (NASH)-associated liver carcinomas.
HepaRegeniX hires industry expert Dr. Markus Weissbach as Senior Clinical Advisor
30 years of specialist knowledge in clinical operations to translate encouraging preclinical results into the clinic.
HepaRegeniX GmbH to deliver an oral presentation of preclinical results on MKK4 inhibition in liver regeneration at The Liver Meeting® 2020
Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models...
HepaRegeniX GmbH hires industry veteran Dr David Shapiro as Senior Medical Advisor
Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models...